

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Mylan Pharmaceuticals Inc., Petitioner

v.

Nissan Chemical Industries Ltd.
Patent Owner

U.S. Patent No. 5,856,336 to Fujikawa *et al.*

Issue Date: January 5, 1999

Title: Quinoline Type Mevalonolactones

Inter Partes Review No.: IPR2015-01069

Petitioners Exhibit List

Petitioner's Exhibit List

<i>Exhibit #</i>	<i>Description</i>
1001	U.S. Patent No. 5,856,336 (“the ’336 patent”)
1002	U.S. Patent No. 5,872,130
1003	U.S. Application Ser. No. 233,752
1004	Japanese Patent Application No. JP 62-207224 with English translation provided by the ’336 patentee from U.S. Application Ser. 07/233,752, related family member of the ’336 patent, with accompanying sworn declaration provided by the patentee to the USPTO attesting to the accuracy of the translation.
1005	Japanese Patent Application No. JP 63-15585 with English translation provided by the ’336 patentee from U.S. Application Ser. 07/233,752, related family member of the ’336 patent, with accompanying sworn declaration provided by the patentee to the USPTO attesting to the accuracy of the translation.
1006	Japanese Patent Application No. JP 63-193606 with English translation provided by the ’336 patentee from U.S. Application Ser. 07/233,752, related family member of the ’336 patent, with accompanying sworn declaration provided by the patentee to the USPTO attesting to the accuracy of the translation.
1007	Curriculum Vitae of Roger Frank Newton, Ph.D.
1008	Declaration of Roger Frank Newton, Ph.D.
1009	Faizulla G. Kathawala, et al., <i>XU 62-320, An HMG-CoA Reductase Inhibitor, More Potent Than Compactin</i> , Abstract for American Chemical Society library stamp July 29, 1987
1010	U.S. Patent No. 4,739,073

<i>Exhibit #</i>	<i>Description</i>
1011	R. G. Engstrom et al., <i>Hypolipoproteinemic Effects of a Potent HMG-CoA Reductase Inhibitor</i> , IX International Symposium on Drugs Affecting Lipid Metabolism, Florence (Italy), Oct. 22-25, 1986
1012	Jonathan A. Tobert, <i>New Developments in Lipid-Lowering Therapy: The Role of Inhibitors of Hydroxymethylglutaryl-Coenzyme A Reductase</i> , 76 CIRCULATION 534 (1987)
1013	Ta-Jyh Lee, <i>Synthesis, SARs and Therapeutic Potential of HMG-CoA Reductase Inhibitors</i> , 8 TRENDS PHARMACOL. SCI. 442 (1987)
1014	Akira Endo et al., <i>ML-236A, ML-236B, and ML-236C, New Inhibitors of Cholesterologenesis Produced by Penicillium Citrinium</i> , 29 J. ANTIBIOTICS 1346 (1976)
1015	Declaration of David Gortler, Pharm.D.
1016	U.S. Patent No. 4,647,576
1017	Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”), FOOD AND DRUG ADMINISTRATION, listing for active ingredient “lovastatin,” available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?AppI_No=019643&TABLE1=OB_Disc (last visited April 13, 2015)
1018	U.S. Patent No. 4,613,610
1019	U.S. Patent No. 4,681,893
1020	U.S. Patent No. 4,751,235
1021	U.S. Patent No. 4,761,419
1022	Alfred W. Alberts, <i>Mevinolin: A Highly Potent Competitive Inhibitor of Hydroxymethylglutaryl-Coenzyme a Reductase and a Cholesterol-Lowering Agent</i> , 77 PROC. NAT’L. ACAD. SCI. U.S.A. 3957 (1980)

<i>Exhibit #</i>	<i>Description</i>
1023	J.B. Taylor & P.D. Kennewell, <i>Introductory Medicinal Chemistry</i> 94 (1981)
1024	Corwin Hansch et al., “ <i>Aromatic</i> ” <i>Substituent Constants for Structure-Activity Correlations</i> , 16 J. MED. CHEM. 1207 (1973) (“Hansch II”)
1025	European Patent No. 0114027
1026	U.S. Patent No. 4,537,859
1027	Stephen M. Berge, <i>Pharmaceutical Salts</i> , 66 J. PHARM. SCI. 1 (1977)
1028	Philip L. Gould, <i>Salt Selection for Basic Drugs</i> , 33 INT. J. PHARM. 201 (1986)
1029	John T. Suh et al., <i>Angiotensin-Converting Enzyme Inhibitors New Orally Active Antihypertensive (Mercaptoalkanoyl)- and [(Acylthio)alkanoyl]glycine Derivatives</i> , 28 J. MED. CHEM. 57 (1985)
1030	Michael S. Brown, M.D. et al., <i>Lowering Plasma Cholesterol by Raising LDL Receptors</i> , 305 NEW ENG. J. MED. 515 (1981)
1031	Fujikawa Reply to the Opposition to Fujikawa et al.’s Motion to Add Counts 3 and 4, received July 21, 1992. U.S. Interference No. 102,608 (“Paper No. 32”)
1032	Declaration of Masaki Kitahara, submitted in the ’336 patent, dated May 25, 1992
1033	O. E. Schultz et al., <i>Schätzung des Verteilungskoeffizienten mit Hilfe Quantenchemischer Molekülgrößen</i> , 25 ZEITSCHRIFT FÜR NATURFORSCHUNG B 1024 (1970), certified English translation included

<i>Exhibit #</i>	<i>Description</i>
1034	Corwin Hansch et al., <i>The Effect of Intramolecular Hydrophobic Bonding on Partition Coefficients</i> , 32 J. ORG. CHEM. 2583 (1967) (“Hansch I”)
1035	European Patent Publication 179,559
1036	I. T. Scoular et al., <i>Human Studies on the Bioavailability of a Quaternary Ammonium Compound, Tiemonium Iodide and Tiemonium Methosulphate</i> , 4 CURR. MED. RES. OPIN. 732 (1977)
1037	Curriculum Vitae of David Gortler, Pharm.D.
1038	David J. Shapiro & Victor W. Rodwell, <i>Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Cholesterol Synthesis</i> , 246 J. BIOL. CHEM. 3210 (1971)
1039	Yoshio Tsujita et al., <i>CS-514, A Competitive Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: Tissue-Selective Inhibition of Sterol Synthesis and Hypolipidemic Effect on Various Animal Species</i> , 877 BIOCHIMICA ET BIOPHYSICA ACTA 50 (1986)
1040	G.E. Stokker et al., <i>3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors. 1. Structural Modification of 5-Substituted 3,5-Dihydroxypentanoic Acids and Their Lactone Derivatives</i> , 28 J. MED. CHEM. 347 (1985) (“Stokker I”)
1041	G.E. Stokker et al., <i>3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors 3. 7-(3,5-Disubstituted [1,1'-biphenyl]-2-yl)-3,5-Dihydroxy-6-Heptenoic Acids and Their Lactone Derivatives</i> , 29 J. MED. CHEM. 170, 175 (1986) (“Stokker II”)
1042	Final Hearing, November 22, 1994. U.S. Interference No. 102,608 (“Paper No. 122”)